chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Had reactions 5 days after vaccination (first dose), nausea, left lymph node on collarbone extremely swollen to the size of a quarter, diarrhea. Went to doctor, supraclavical lymph node swollen, doctor believe it is vaccine. Still swollen after several months. Went back to doctor, lymph node not hard.
experiencing unbearable pain on the arm where she got injected; This spontaneous report from contactable consumer (patient) via medical information department.  A 69-year-old female patient received BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number: not reported), via an unspecified route of administration, on unspecified date (age at vaccination: 69 years), as a dose 2, single for COVID-19 immunization. The patients medical history and concomitant medications were not reported. The patient reported that she has been experiencing unbearable pain on the arm where she got the injection. Patient wanted to know if this was normal, or this has been reported before. Outcome for the event was unknown.   The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Dull pain in heart; Left arm hurt a bit; This spontaneous case was reported by a consumer and describes the occurrence of ANGINA PECTORIS (Dull pain in heart) in a 31-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Apr-2021, the patient experienced ANGINA PECTORIS (Dull pain in heart) (seriousness criterion medically significant) and PAIN IN EXTREMITY (Left arm hurt a bit). At the time of the report, ANGINA PECTORIS (Dull pain in heart) and PAIN IN EXTREMITY (Left arm hurt a bit) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  Treatment information was not provided.  Company Comment - Based on the current available information and temporal association between the use of the product, and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product, and the start date of the events, a causal relationship cannot be excluded.
vaccine was frozen rather than refrigerated. dose was given to patient. no symptoms reported.  revaccination offered.
Patient admitted on 009/07/2005 with 1 week history of strange behavior, bad mood, difficulty with ambulation, abnormal gait coordination, and incoherent speech. Also had a history of subjective fever at home.
Rash on face 2 days p/immun; t100.1-rash went away p/1 wk; Seen by MD a couple of wks later was told had allergic rxn to immun; Not seen by MD p/rash appeared;
lethargic; warm; tired; fever of 99.5, unusual; This spontaneous case was reported by a consumer and describes the occurrence of LETHARGY (lethargic), FEELING HOT (warm), FATIGUE (tired) and PYREXIA (fever of 99.5, unusual) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046B21A) for COVID-19 vaccination.      The patient's past medical history included Multiple myeloma. Concomitant products included GABAPENTIN, NALOXEGOL OXALATE (MOVANTIK) and FENTANYL CITRATE (NARCO) for an unknown indication.    On 13-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Apr-2021, the patient experienced LETHARGY (lethargic), FEELING HOT (warm), FATIGUE (tired) and PYREXIA (fever of 99.5, unusual). At the time of the report, LETHARGY (lethargic), FEELING HOT (warm), FATIGUE (tired) and PYREXIA (fever of 99.5, unusual) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 99.5 (Inconclusive) 99.5 degree Celsius.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information in response to events was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 14-Apr-2021: Follow up received on 15-APR-2021 Contains Reporter details and concomitant medication was updated
nausea; injection site pain; lightheadedness; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (lightheadedness), NAUSEA (nausea) and VACCINATION SITE PAIN (injection site pain) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Gastroesophageal reflux disease. Concomitant products included OMEPRAZOLE MAGNESIUM (PRILOSEC [OMEPRAZOLE MAGNESIUM]) and OMEPRAZOLE (PROTONIX [OMEPRAZOLE]) for an unknown indication.    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced DIZZINESS (lightheadedness) and VACCINATION SITE PAIN (injection site pain). On 25-Jan-2021, the patient experienced NAUSEA (nausea). On 23-Jan-2021, DIZZINESS (lightheadedness) had resolved. On 24-Jan-2021, VACCINATION SITE PAIN (injection site pain) had resolved. At the time of the report, NAUSEA (nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
A report has been received from a Health Professional concerning a 7 year old, female subject, who had been receiving Nasal FLUMIST QUADRIVALENT (INTRANASAL). FLUMIST QUADRIVALENT (INTRANASAL) started on 27-Jan-2014. It was reported that the patient was inadvertently administered expired FLUMIST QUADRIVALENT on 27-Jan-2014. The outcome of the event of inadvertently administered expired FLUMIST QUADRIVALENT is unknown. The report was considered to be non-serious.
I felt absolutely horrible the day after my vaccine.  Feeling pretty under the weather and sick for a week.  I've had two migraines.  Today - a week after my shot - my arm is swollen, red, very hot, very painful, and a little itchy. I also feel pretty ill and strange.  I was also prescribed metronidazole and started that two days ago, and am wondering if that would contribute to this reaction.
ADMINISTRATION ERROR 2ND SHOT GIVEN; ACHES; HAIR HURT (PHANTOM HAIR PAIN); RELATIVE HYPOTENSION; UNCONTROLLABLE RIGORS; FEVER; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date, the subject experienced administration error 2nd shot given, aches, hair hurt (phantom hair pain), relative hypotension, uncontrollable rigors, and fever. Treatment medications (dates unspecified) included: ibuprofen. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from fever, aches, hair hurt (phantom hair pain), relative hypotension, and uncontrollable rigors, and the outcome of administration error 2nd shot given was not reported. This report was non-serious.
palpitations; fatigue; This is a spontaneous report from a contactable consumer (patient) reported for herself that a 41-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EN6204) at the age of 41-years, via an unspecified route of administration in left arm on 09Mar2021 15:15 at single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Patient was not pregnant at the time of vaccination. No allergies to medications, food, or other products. Concomitant medications were not reported. The patient experienced palpitations and fatigue on 19Mar2021. The events result in emergency room/department or urgent care. Treatment was received for the adverse events. The patient underwent lab tests and procedures, which included X-Ray, Cat scan and Blood work, all with unknown results on unspecified date. Since the vaccination, the patient has not been tested for COVID-19. Outcome of the events was not recovered/not resolved.   No follow-up attempts are needed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021371063 same patient/SD, different AE/dose
lumps on her face (one on the forehead and another one on the nose which extends down to her lower cheek)/lumps on her left lower arm (on the elbow and wrist); lumpy red rash on her left armpit; cellulitis; This spontaneous case was reported by a patient (subsequently medically confirmed) and describes the occurrence of CELLULITIS (cellulitis) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027B21A and 031A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 04-May-2021, the patient experienced MASS (lumps on her face (one on the forehead and another one on the nose which extends down to her lower cheek)/lumps on her left lower arm (on the elbow and wrist)) and RASH ERYTHEMATOUS (lumpy red rash on her left armpit). In May 2021, the patient experienced CELLULITIS (cellulitis) (seriousness criterion medically significant). At the time of the report, CELLULITIS (cellulitis), MASS (lumps on her face (one on the forehead and another one on the nose which extends down to her lower cheek)/lumps on her left lower arm (on the elbow and wrist)) and RASH ERYTHEMATOUS (lumpy red rash on her left armpit) had not resolved.            Concomitant medications were not provided.  Patient consulted a dermatologist who initially  thought it was cellulitis for which a blood test and puncture biopsy was done and also given a unspecified medicine but it did not resolve. She was then referred to neurologist and MRI was done and awaiting results. The lumps were still present at the time of the call.  Company comment: Very limited information regarding this event/s has been provided at this time. Further information has been requested; Sender's Comments: Very limited information regarding this event/s has been provided at this time. Further information has been requested
This case was reported by a nurse and described the occurrence of pain in upper quadrant in a 33 year old  male subject who was vaccinated with hepatitis B vaccine recombinant (Engerix B) for prophylaxis. Medical history included non smoker and allergy to some antibiotics, allergy to prednisone and upset stomach. There were no concurrent medications. On June 24 2005 the subject received the 1st dose of Engerix B in the left arm. On June 26 2005, two days after the vaccination with the first dose of Engerix B, the subject experienced pain in upper right quadrant, gastrointestinal upset, dizziness, headache, and weakness. The events resolved five days later, on 6/30/2005. On Aug 3 2005, the subject received the second dose of Engerix B. This is longer than the recommended interval of one month between the first and second doses of Engerix B. On Aug 5 2005, two days following receipt of the second dose of Engerix B, the subject again experienced pain in upper right quadrant, gastrointestinal upset, dizziness, headache, and weakness, but with greater intensity, and fever, racing heart, and injection site soreness. The events resolved eight days later, on 8/12/2005, and 4 days of that week were spent in bed due to weakness.
A non-serious, spontaneous report of fever, congestion, muscle aches and sore throat was received from a consumer, concerning an adult female subsequent to FLUMIST. Neither relevant medical history nor concomitant medications have been reported for this patient. The patient received FLUMIST on 22-Oct-2008. Forty-eight hours after administration the patient experienced symptoms of low grade fever, congestion, muscle aches and sorer throat. The symptoms were ongoing at the time of reporting on 30-Oct-2008.
This spontaneous report was received from a physician via company representative and refers to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions or allergies were not reported. On 30-JUL-2015, the patient was vaccinated with an improperly stored PEDVAXHIB Single Dose Vaccine, 10-pack, lot number K004541, expiration date 04-DEC-2016, (dose, route and anatomical location were not reported). The improperly stored PEDVAXHIB was in a Refrigerator, and, the highest temperature of excursion was 47 Fahrenheit degrees (8.33 Celsius degrees) with a sum of 24 hours of excursion. No adverse effects were reported and no product quality complain was involved. This is one of several reports from the same reporter. Additional information has been requested.
About an hour after the vaccine, My throat started to really hurt, nose was sneezing and coughing. I took Allegra D and Flonase. I also had a bad headache,full body aches, ear pain, and still neck. I had no fever. My symptoms continue to worsen. My nerve disorder also flared. The symptoms of my flare up includes tingling in my legs, feeling cold or very hot, creepy crawling sensations, and restless legs. I did go see the doctor (virtual md) and was initally prescribed muscle relaxer Cyclobenzaprine for my stiff neck. I then went to a 2nd doctor (in person visit) and I was prescribed Methylprednisolone, Amoxicillin, and Fluconazole. The medications are helping and I am feeling much better. I was against taking the vaccine but my employer has mandated it.
Pain at injection site; This is a spontaneous report from a contactable nurse (patient). A 51-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot EH9899) intramuscular from 16Dec2020 22:00 at a single dose on the left arm as COVID-19 vaccine. Medical history included ulcerative colitis. The patient had no known allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine and did not receive other medications within 2 weeks of vaccination (no other vaccine in four weeks and no other medications in two weeks). The patient experienced pain at injection site on 16Dec2020 23:00. Treatment was not received for the adverse event. The patient had no Covid prior vaccination and did not have Covid tested post vaccination. The event was assessed as non-serious, did not result in death, not life threatening, did not cause/prolonged hospitalization, not disabling/incapacitating, did not cause congenital anomaly/birth defect. The patient was not pregnant at the time of vaccination. The most recent COVID-19 vaccine was administered at the hospital. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The outcome of the event was recovering.
After receiving MCV4, while seated, client moved forward, passed out, slipped to the floor.  Patient was lying prone on floor, arms at sides, with jerking movements in arms.  Patient recovered quickly, rolled onto back, cool compress applied to forehead.  Offered water, and patient remained in supine position.  After a few minutes, patient helped up and assisted to exam room to lay on exam table for 15 minutes.  Patient awake alert, color good, BP 112/68, offered crackers.  Color good.  Cool compress to left ear.  Slight scrap to left cheek area.  Patient then stood and walked without assistance.  Follow-up phone call 8/4/09, spoke to patient who verbally reported no other problems over weekend.
pt recv vax & c/o hands tingled p/inj;the reporter stated there was no active disease present @ the time & recommended pt see MD;
This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of CEREBRAL VENOUS SINUS THROMBOSIS (Cerebral Venous Sinus Thrombosis) and HEADACHE (headache) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016B21A) for COVID-19 vaccination. Concomitant products included ETHINYLESTRADIOL, NORGESTREL (CONTRACEPTIVE HD) for Birth control. On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Mar-2021, the patient experienced HEADACHE (headache) (seriousness criterion hospitalization prolonged). On 02-Apr-2021, the patient experienced CEREBRAL VENOUS SINUS THROMBOSIS (Cerebral Venous Sinus Thrombosis) (seriousness criterion hospitalization prolonged). The patient was hospitalized from 02-Apr-2021 to 06-Apr-2021 due to CEREBRAL VENOUS SINUS THROMBOSIS and HEADACHE. At the time of the report, CEREBRAL VENOUS SINUS THROMBOSIS (Cerebral Venous Sinus Thrombosis) had not resolved, and HEADACHE (headache) outcome was unknown. Not Provided, DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 02-Apr-2021, Computerized tomogram: abnormal (abnormal) Cerebral Venus Thrombosis in the brain. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. Treatment of the events included Pradaxa. Company comment: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded. However, the patient's recent history of starting back on oral contraceptives may remain a risk factor for this event.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded. However, the patient's recent history of starting back on oral contraceptives may remain a risk factor for this event.
Our employee was administered this dose of influenza vaccine at a remote clinical location by another staff member at that location.  After administration, the vaccinator was documenting the dose and realized that this lot  9JD9K had expired on 6/30/2022, and was not the current season's influenza lot.  A second dose with the current year, unexpired influenza vaccine( Flulaval GF9PM expiration 6/30/2023)  was then administered the same day, 11/15/22.  No adverse reactions were reported by the vaccine recipient after receiving these two doses in the same day. The expired vaccine lot was disposed of immediately.
Pt recvd vax & 12 hrs p/dose 3 exp itching on legs (no rash); treatment DPH, Atarax, topical steroids & pred;
This case was reported by a physician via sales representative and described the occurrence of extensive swelling of vaccinated limb in a 4-year-old female subject who was vaccinated with KINRIX (GlaxoSmithKline). Concurrent vaccination included PROQUAD (non-gsk); Merck; unknown; unknown given on 2 October 2013. On 2 October 2013 the subject received a dose of KINRIX (unknown details, right thigh) as the 5th dose of the DTaP series. "Late in the night" on 2 October 2013, within hours of vaccination with KINRIX, the subject experienced extensive swelling of vaccinated limb, chest pain, throat pain, vomiting, injection site rash, welt injection site, and vaccine administered at inappropriate site. The physician reported that the subject experienced a "3 by 5 inch" (76.2 by 127 millimeters) welt on the right thigh. The subject sought medical attention at the doctor's office. The preferred site of administration for KINRIX is the deltoid of the upper arm. At the time of reporting the events were resolved. No other details were provided at the time of reporting. Follow up was received from the physician on 29 October 2013. The physician documented that the subject was diagnosed with an injection reaction. Symptoms onset on 2 October 2013. The outcomes for the events were not mentioned; however, previously the physician documented that the events had resolved. The physician identified KINRIX as the suspect product. The physician did not consider this case serious. The events did not involved a congenital anomaly or birth defect. The physician noted that no subsequent doses were given at the time of this reporting. The subject had not experienced any adverse events following previous vaccinations per the physician.
The second dose of the Pfizer Covid Vaccine primary series was given on day 14 after the 1st dose in the primary series. This is too early and needs to be repeated after the recommended minimum interval.
extreme pain and limited ability to lift or use left arm; continue to have minimal although perceptible discomfort in left arm from elbow down
Patient complained of chest pain (CP), approx 5 days after vaccine.   Saw one of the clinic doctors before receiving 2nd vaccine but again reported worsening chest pain after second COVID vaccine, Pfizer, Lot # FF8841. Given on  11/18/21. Seen in ED approx  2 weeks after for worsening CP since second dose, also complaints of SOB and Dizzy
pt recv vax 1JUL95 & on 27NOV97 pt devel chickenpox d/t lack of serconversion;
This spontaneous report as received from a pharmacist refers to a 81 year old female patient. The patient's medical history included tuberculosis for which she was treated "for a year or more". The reporting pharmacist could not clarify whether or not patient had any other disease states. On an unspecified date in approximately September 2008 also reported as "approximately 6 years ago", the patient was vaccinated with the first dose of PNEUMOVAX23 (route of administration, indication and lot # were not specified). After she was treated "for a year or more" for tuberculosis, she was prescribed to receive a second dose of PNEUMOVAX23 as recommended her physician. On 26-SEP-2014 also reported as "today", the patient was vaccinated with expired dose of PNEUMOVAX23 (second dose, route of administration was not specified (lot # H022280, exp date: 16-JUL-2014). The reporting pharmacist stated that when he looked at the expiration date on the vial, 16-JUL-2014, he initially thought the expiration date was the 14-JUL-2016. After the dose of PNEUMOVAX23 was administered to the patient and the pharmacist was documenting the administration, he realized that the date was actually referring to 16-JUL-2014. No adverse experience was observed or reported. No product quality complaint (PQC) was involved. Additional information has been requested.
Patient developed 103.7 fever about 24 hours after immunizations, and then large indurated erythema on both thighs, 4-5 cm in diameter.  Mildly tender.
2/20/2021 Within 10 minutes of receiving the vaccine,  sinus congestion and thickening of the throat, coughing, lightheaded, tachycardia.  Administered epinephrine from auto injector by nurse at clinic.  Administered Benadryl by EMS & EKG was completed  At ED administered IV steroid and Pepcid. Observed for four hours and sent home  2/22/2021 - @ 6:55 am Secondary reaction occurred with sinus congestion and thickening of the throat, coughing, lightheaded, tachycardia.  Administered epinephrine from auto injector by nurse, EMS was called  Administered Benadryl by EMS & EKG was completed  At ED administered IV steroid and Pepcid. Observed for four hours and sent home